Last reviewed · How we verify
aerosolized vancomycin
At a glance
| Generic name | aerosolized vancomycin |
|---|---|
| Sponsor | National Cancer Institute (NCI) |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Study of Aerosolized Antibiotics and Pembrolizumab in Advanced Non-small Cell Lung Cancer (PHASE1)
- Aerosolized Antibiotics in the Treatment of Ventilator Associated Pneumonia (PHASE4)
- Pharmacokinetics of Vancomycin for Inhalation in Cystic Fibrosis (PHASE1)
- Aerosolized Vancomycin in Methicillin-Resistant Staphylococcus Aureus Pneumonia Under Mechanical Ventilation (PHASE2)
- Reduction of Bacterial Resistance With Inhaled Antibiotics in the Intensive Care Unit (EARLY_PHASE1)
- Aerosolized Antibiotics and Respiratory Tract Infection in Patients on Mechanical Ventilation (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- aerosolized vancomycin CI brief — competitive landscape report
- aerosolized vancomycin updates RSS · CI watch RSS
- National Cancer Institute (NCI) portfolio CI